| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
SMOKING |
1 UBC McDonald Research Laboratories/iCAPTURE Center, Vancouver, BC, Canada
2 Division of Biostatistics, School of Public Health, University of Minnesota Minneapolis, MN, USA
3 Faculty of Medicine, University of Manitoba, Winnipeg, MB, Canada
4 Canadian HIV Trials Network, St Paul’s Hospital, Vancouver, BC, Canada
Correspondence to:
Correspondence to:
Dr A J Sandford, UBC McDonald Research Laboratories, Room 292, St Paul’s Hospital, 1081 Burrard Street, Vancouver, BC, Canada V6Z 1Y6;
asandford{at}mrl.ubc.ca
ABSTRACT
Background: Non-specific bronchial hyperresponsiveness (NSBH) is a known predictor of accelerated rate of decline in lung function in smokers. Polymorphisms of the ß2 adrenergic receptor (ADRB2) have previously been associated with NSBH and bronchodilator response (BDR) in asthmatics. Based on these associations, we hypothesised that ADRB2 polymorphisms would be associated with NSBH and BDR as well as an accelerated rate of decline in lung function among smokers.
Methods: The prevalence of two ADRB2 polymorphisms, Arg16
Gly and Gln27Glu, was examined in 587 smokers chosen from the NHLBI Lung Health Study for having the fastest (n=282) and slowest (n=305) 5 year rate of decline in forced expiratory volume in 1 second (FEV1; mean 
FEV1 -4.14 and +1.08% predicted/year, respectively).
Results: Contrary to our hypothesis, no ADRB2 allele or haplotype was associated with NSBH, BDR, or rate of decline in lung function. However, there was a significant negative association between heterozygosity at position 27 and a fast decline in lung function (adjusted odds ratio 0.56, 95% CI 0.40 to 0.78, p=0.0007).
Conclusions: Heterozygosity at position 27 may be protective against an accelerated rate of decline in lung function. The polymorphism at position 16 does not contribute to the rate of decline in lung function, measures of NSBH, or BDR in smokers.
Keywords: bronchial provocation tests; lung volume measurements; chronic obstructive pulmonary disease; genetics; ß2 adrenergic receptors
This article has been cited by other articles:
|
|
 |
|
  C. P. Hersh, D. L. DeMeo, and E. K. Silverman National Emphysema Treatment Trial State of the Art: Genetics of Emphysema Proceedings of the ATS, May 1, 2008; 5(4): 486 - 493. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Zhang, C. M. Hayden, S-K. Khoo, P. Candelaria, I. A. Laing, S. Turner, P. Franklin, S. Stick, L. Landau, J. Goldblatt, et al. {beta}2-Adrenoceptor polymorphisms and asthma phenotypes: interactions with passive smoking Eur. Respir. J., July 1, 2007; 30(1): 48 - 55. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F Castro-Giner, F Kauffmann, R de Cid, and M Kogevinas Gene-environment interactions in asthma. Occup. Environ. Med., November 1, 2006; 63(11): 776 - 761. [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. Taylor, M. J. Epton, M. A. Kennedy, A. D. Smith, S. Iles, A. L. Miller, M. D. Littlejohn, J. O. Cowan, T. Hewitt, M. P. Swanney, et al. Bronchodilator Response in Relation to {beta}2-Adrenoceptor Haplotype in Patients with Asthma Am. J. Respir. Crit. Care Med., September 15, 2005; 172(6): 700 - 703. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. E. Hegab, T. Sakamoto, W. Saitoh, H. H. Massoud, H. M. Massoud, K. M. Hassanein, and K. Sekizawa Polymorphisms of IL4, IL13, and ADRB2 Genes in COPD Chest, December 1, 2004; 126(6): 1832 - 1839. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. A. Molfino Genetics of COPD Chest, May 1, 2004; 125(5): 1929 - 1940. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C E Ruse and S G Parker Genetics and the Dutch Hypothesis Chronic Respiratory Disease, April 1, 2004; 1(2): 105 - 113. [Abstract] [PDF]
|
|
Read all eLetters
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
